Back to News
Feb 5, 2026 4:00 PM

Hims & Hers Launches Compounded Version Of Wegovy, Novo Nordisk Threatens Legal Action

On Thursday, Hims & Hers Health Inc. (NYSE:HIMS) announced Thursday an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Novo Nordisk A/S' (NYSE:NVO) Wegovy.

Starting today, eligible customers can access treatment plans that include Compounded Semaglutide Pills at a special introductory offer starting at just $49 for the first month.

The new Compounded Semaglutide Pill is formulated to protect the active ingredient during digestion and to support absorption.

In 2025, Hims & Hers doubled its facility footprint to over one million square feet, integrating advanced pharmacy capabilities, lab testing, and R&D space.

Hims & Hers said it adheres to all applicable federal and state regulatory standards for ...